No Data
No Data
Hisense Pharmaceutical (001367.SZ): Net profit of 33.3848 million yuan in the first quarter increased 33.55% year-on-year
Gelonghui, April 24 | Hisense Pharmaceutical (001367.SZ) released its report for the first quarter of 2024, with operating income of 116 million yuan, up 8.27% year on year; net profit attributable to shareholders of listed companies was 33.3848 million yuan, up 33.55% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 32.641 million yuan, up 30.49% year on year; basic earnings per share were 0.49 yuan.
Hisense Pharmaceutical (001367.SZ): Net profit of 105 million yuan in 2023, plans to convert 10 to 4.8 to 5 yuan
Gelonghui, April 22丨Hysen Pharmaceutical (001367.SZ) announced its 2023 annual report. Operating income for the reporting period was 397 million yuan, down 5.99% year on year; net profit attributable to shareholders of listed companies was 105 million yuan, down 2.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 101 million yuan, down 0.14% year on year; basic income per share was 1.68 yuan; it plans to distribute a cash dividend of 5 yuan (tax included) for every 10 shares to all shareholders.
Heisen Pharmaceutical (001367.SZ): Currently, the company does not produce azithromycin
Glonghui, Oct. 23 | An investor asked Heisen Pharmaceutical (001367.SZ) on the investor interactive platform, “Does the company produce azithromycin?” The company replied that the company currently has a product system that mainly uses digestive, antipyretic, analgesic, and cardiovascular APIs, complemented by APIs such as antidepressants and antimicrobials, and is also prepared with special APIs and preparations such as antiviral and non-steroidal anti-inflammatory drugs. Currently, the company does not produce azithromycin.
Hisen Pharmaceutical (001367.SZ) will list 341,600 restricted shares for circulation on October 17
Hisen Pharmaceutical (001367.SZ) announced that the number of shareholders whose share sales restrictions have been lifted this time is 7,711. The explanation...
Heisen Pharmaceutical (001367.SZ): The main products currently under development include APIs and pharmaceutical products
Glonghui, Oct. 10丨Hyssen Pharmaceutical (001367.SZ) said on the investor interactive platform that the main products currently being developed by the company include APIs and pharmaceutical products.
Haisen Pharmaceutical to Invest 3 Billion Yuan on New Factory
Zhejiang Haisen Pharmaceutical (SHE:001367) has earmarked 3 billion yuan on a new factory within the Zhejiang Dongyang Economic Development Zone. The Chinese pharmaceutical ingredients and intermediat
No Data